Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

51.65 +0.86 (+1.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,047,057
Open 50.62
Bid (Size) 50.24 (200)
Ask (Size) 52.00 (200)
Prev. Close 50.79
Today's Range 50.48 - 51.72
52wk Range 32.15 - 51.72
Shares Outstanding 388,132,400
Dividend Yield 1.82%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why One Fund’s $4 Million Centerra Gold Exit Looks Like Profit-Taking Amid a 150% Rally ↗
Centerra Gold operates integrated mining projects in North America and Turkey, generating revenue from gold, copper, and molybdenum sales. 
Via The Motley Fool
News headline image
This Fund Cashed Out of Preformed Line Products Amid a 150% Stock Surge ↗
Preformed Line Products designs and manufactures network hardware for utilities and telecoms across global infrastructure markets. 
Via The Motley Fool
Topics Regulatory Compliance Supply Chain

Performance

YTD
+32.9%
+32.9%
1 Month
+7.8%
+7.8%
3 Month
+17.3%
+17.3%
6 Month
+34.0%
+34.0%
1 Year
+54.9%
+54.9%

More News

Read More
News headline image
Royalty Pharma to present at upcoming investor conferences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma (RPRX) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Royalty Pharma (NASDAQ:RPRX) Beats Q1 Estimates and Raises Guidance, Fueling Strong Momentum ↗
Via Chartmill
News headline image
Royalty Pharma reports first quarter 2026 results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings
Via StockStory
Topics Artificial Intelligence
News headline image
3 Unpopular Stocks We’re Skeptical Of
Via StockStory
News headline image
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma PLC (NASDAQ:RPRX) Emerges as a Compelling Value Investment ↗
Via Chartmill
ROYALTY PHARMA PLC-CL A (NASDAQ:RPRX) Shows High Technical and Setup Ratings Ahead of Potential Breakout ↗
Via Chartmill
News headline image
Royalty Pharma Declares Second Quarter 2026 Dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026
From Royalty Pharma plc
Via GlobeNewswire
News headline image
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds
Via StockStory
News headline image
Branded Pharmaceuticals Stocks Q4 Teardown: Royalty Pharma (NASDAQ:RPRX) Vs The Rest
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Value Stock for Long-Term Investors and 2 Facing Challenges
Via StockStory
News headline image
1 Cash-Producing Stock to Own for Decades and 2 That Underwhelm
Via StockStory
Topics Energy
News headline image
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
From Royalty Pharma plc
Via GlobeNewswire
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
Via Finterra
Topics Economy Initial Public Offering
News headline image
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q4 Earnings?
Via StockStory
Topics Artificial Intelligence Stocks Supply Chain
News headline image
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Expansion of Leadership Team
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
From Zymeworks Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Royalty Pharma plc - Class A Ordinary Shares publicly traded?
Yes, Royalty Pharma plc - Class A Ordinary Shares is publicly traded.
What exchange does Royalty Pharma plc - Class A Ordinary Shares trade on?
Royalty Pharma plc - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Royalty Pharma plc - Class A Ordinary Shares?
The ticker symbol for Royalty Pharma plc - Class A Ordinary Shares is RPRX on the Nasdaq Stock Market
What is the current price of Royalty Pharma plc - Class A Ordinary Shares?
The current price of Royalty Pharma plc - Class A Ordinary Shares is 51.65
When was Royalty Pharma plc - Class A Ordinary Shares last traded?
The last trade of Royalty Pharma plc - Class A Ordinary Shares was at 05/11/26 04:00 PM ET
What is the market capitalization of Royalty Pharma plc - Class A Ordinary Shares?
The market capitalization of Royalty Pharma plc - Class A Ordinary Shares is 20.05B
How many shares of Royalty Pharma plc - Class A Ordinary Shares are outstanding?
Royalty Pharma plc - Class A Ordinary Shares has 20B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.